A Study of LY2409021 in Participants With Type 2 Diabetes Mellitus

Stopped The overall benefit-risk profile did not support continued development of LY2409021 for type 2 diabetes.

Conditions

• Diabetes Mellitus, Type 2

Interventions

• DRUG: LY2409021
• DRUG: Sitagliptin
• DRUG: Placebo
• DRUG: Metformin
• DRUG: Sulfonylurea

Sponsor

Eli Lilly and Company